Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotransformation and elimination as inactive metabolites. These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed. Remimazolam was the first "soft" benzodiazepine analog to be developed and was approved for use by the FDA in July 2020 under the brand name Byfavo.
Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.
Kangbuk Samsung Hospital, Seoul, Korea, Republic of
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
the Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China
the Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China
the Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China
Wonkwag UH, Iksan, Jeollabukdo, Korea, Republic of
Sanggye Paik hospital, Seoul, Korea, Republic of
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.